Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756850 | 0.97 | CA2 (0.50) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL2053132 | 0.86 | CA2 (0.59) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL18160927 | 0.80 | CA2 (0.53) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL6971654 | 0.78 | CA2 (0.50) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL6971647 | 0.78 | CA2 (0.50) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL8589178 | 0.75 | CA2 (0.48) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL6972222 | 0.75 | CA2 (0.48) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL6972226 | 0.75 | CA2 (0.48) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL1618655 | 0.73 | CA2 (0.46) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL14477917 | 0.73 | CA2 (0.46) | CA2ALDH1A1POLBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023162429-A1 | SECONDARY BATTERY ELECTROLYTE AND SECONDARY BATTERY | 株式会社村田製作所 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023162430-A1 | SECONDARY BATTERY ELECTROLYTE AND SECONDARY BATTERY | 株式会社村田製作所 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023162431-A1 | SECONDARY BATTERY ELECTROLYTE AND SECONDARY BATTERY | 株式会社村田製作所 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023119948-A1 | SECONDARY BATTERY | 株式会社村田製作所 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023119945-A1 | SECONDARY BATTERY ELECTROLYTE SOLUTION AND SECONDARY BATTERY | 株式会社村田製作所 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023120688-A1 | SECONDARY BATTERY | 株式会社村田製作所 | 2023-06-29 | — | — | WO | disclosed |
| US-20100093817-A1 | Compounds | BIAL - PORTELA & CA S.A. (PT) | 2010-04-15 | — | — | US | disclosed |
| EP-2121668-A2 | 6,8-DICHLORCHROMAN-3-YL-1,3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | BIAL - Portela & Ca., S.A. (PT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008094054-A2 | 6, 8-DICHLORCHROMAN-3-YL-L, 3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | BIAL-PORTELA & CA, S.A. (PT) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093817-A1 | Compounds | TPMT, CYP2C8, ABL1 | CA2 2315/4885ALDH1A1 228/4885POLB 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.